Integrated BioPharma Statistics
Total Valuation
Integrated BioPharma has a market cap or net worth of 7.52 million. The enterprise value is 7.64 million.
| Market Cap | 7.52M |
| Enterprise Value | 7.64M |
Important Dates
The last earnings date was Friday, September 20, 2024.
| Earnings Date | Sep 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Integrated BioPharma has 30.10 million shares outstanding. The number of shares has increased by 3.09% in one year.
| Shares Outstanding | 30.10M |
| Shares Change (YoY) | +3.09% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 14.96% |
| Owned by Institutions (%) | 0.07% |
| Float | 22.17M |
Valuation Ratios
The trailing PE ratio is 68.90.
| PE Ratio | 68.90 |
| Forward PE | n/a |
| PS Ratio | 0.15 |
| PB Ratio | 0.39 |
| P/FCF Ratio | 19.29 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.85, with an EV/FCF ratio of 19.60.
| EV / Earnings | 68.24 |
| EV / Sales | 0.15 |
| EV / EBITDA | 4.85 |
| EV / EBIT | 30.45 |
| EV / FCF | 19.60 |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 9.35.
| Current Ratio | 2.92 |
| Quick Ratio | 1.04 |
| Debt / Equity | 9.35 |
| Debt / EBITDA | 1.14 |
| Debt / FCF | 4.61 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 0.59% and return on invested capital (ROIC) is 0.74%.
| Return on Equity (ROE) | 0.59% |
| Return on Assets (ROA) | 0.61% |
| Return on Capital (ROIC) | 0.74% |
| Revenue Per Employee | 342,293 |
| Profits Per Employee | 762 |
| Employee Count | 141 |
| Asset Turnover | 1.95 |
| Inventory Turnover | 4.32 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.41% in the last 52 weeks. The beta is 0.66, so Integrated BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -7.41% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.24 |
| Relative Strength Index (RSI) | 69.77 |
| Average Volume (20 Days) | 15,195 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, Integrated BioPharma had revenue of 50.32 million and earned 112,000 in profits. Earnings per share was 0.00.
| Revenue | 50.32M |
| Gross Profit | 3.88M |
| Operating Income | 251,000 |
| Pretax Income | 268,000 |
| Net Income | 112,000 |
| EBITDA | 570,000 |
| EBIT | 251,000 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 1.68 million in cash and 1.80 million in debt, giving a net cash position of -121,000 or -0.00 per share.
| Cash & Cash Equivalents | 1.68M |
| Total Debt | 1.80M |
| Net Cash | -121,000 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 19.24M |
| Book Value Per Share | 0.64 |
| Working Capital | 11.75M |
Cash Flow
In the last 12 months, operating cash flow was 943,000 and capital expenditures -553,000, giving a free cash flow of 390,000.
| Operating Cash Flow | 943,000 |
| Capital Expenditures | -553,000 |
| Free Cash Flow | 390,000 |
| FCF Per Share | 0.01 |
Margins
Gross margin is 7.72%, with operating and profit margins of 0.50% and 0.22%.
| Gross Margin | 7.72% |
| Operating Margin | 0.50% |
| Pretax Margin | 0.53% |
| Profit Margin | 0.22% |
| EBITDA Margin | 1.13% |
| EBIT Margin | 0.50% |
| FCF Margin | 0.78% |
Dividends & Yields
Integrated BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.09% |
| Shareholder Yield | -3.09% |
| Earnings Yield | 1.45% |
| FCF Yield | 5.18% |
Stock Splits
The last stock split was on July 2, 1996. It was a reverse split with a ratio of 0.25.
| Last Split Date | Jul 2, 1996 |
| Split Type | Reverse |
| Split Ratio | 0.25 |
Scores
Integrated BioPharma has an Altman Z-Score of 1.43. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.43 |
| Piotroski F-Score | n/a |